L

Liaoning Cheng Da Co Ltd
SSE:600739

Watchlist Manager
Liaoning Cheng Da Co Ltd
SSE:600739
Watchlist
Price: 9.59 CNY -0.72% Market Closed
Market Cap: 14.7B CNY
Have any thoughts about
Liaoning Cheng Da Co Ltd?
Write Note

Liaoning Cheng Da Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Liaoning Cheng Da Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
L
Liaoning Cheng Da Co Ltd
SSE:600739
Note Receivable
ÂĄ179.6m
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
X
Xinhua Winshare Publishing and Media Co Ltd
SSE:601811
Note Receivable
ÂĄ14.8m
CAGR 3-Years
-55%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
A
Anhui Xinhua Media Co Ltd
SSE:601801
Note Receivable
ÂĄ94.2m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sinomach Automobile Co Ltd
SSE:600335
Note Receivable
ÂĄ120.9k
CAGR 3-Years
-95%
CAGR 5-Years
-87%
CAGR 10-Years
N/A
Zhejiang Orient Financial Holdings Group Co Ltd
SSE:600120
Note Receivable
ÂĄ7.2B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
20%
Wuchan Zhongda Group Co Ltd
SSE:600704
Note Receivable
ÂĄ12.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
27%
No Stocks Found

Liaoning Cheng Da Co Ltd
Glance View

Market Cap
14.6B CNY
Industry
Distributors

Liaoning Cheng Da Co Ltd stands as a significant player in the landscape of Chinese conglomerates, weaving a diverse portfolio that strategically aligns with the economic growth patterns of the region. Founded in the bustling province of Liaoning, the company epitomizes a model of diversified investment, underpinning its operations with a well-considered spread across various sectors. Initially, it carved a niche in the trading business, leveraging the abundant natural resources and industrial outputs of its home province to build a steady stream of revenue. This foundation allowed Cheng Da to expand into pharmaceuticals, real estate, and financial investments, each segment contributing distinctively to the company’s overall robustness. Cheng Da’s pharmaceutical business has emerged as a cornerstone, thriving amidst the rising demand for healthcare products in China. This arm of the company is particularly adept in leveraging advanced research methodologies combined with traditional Chinese medicine, thus creating a distinctive edge in both domestic and international markets. Meanwhile, its real estate ventures capably ride the wave of urbanization in China, focusing on premium residential and commercial properties, enhancing the urban landscape while adding to its financial metrics. By sitting at the crossroads of critical sectoral developments and maintaining a keen eye on expansive opportunities, Liaoning Cheng Da Co Ltd astutely navigates the intricate dance of market dynamics, thus cementing its place as a formidable entity in the economic engine of China.

Intrinsic Value
14.52 CNY
Undervaluation 34%
Intrinsic Value
Price
L

See Also

What is Liaoning Cheng Da Co Ltd's Note Receivable?
Note Receivable
179.6m CNY

Based on the financial report for Sep 30, 2024, Liaoning Cheng Da Co Ltd's Note Receivable amounts to 179.6m CNY.

What is Liaoning Cheng Da Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
0%

Over the last year, the Note Receivable growth was -18%. The average annual Note Receivable growth rates for Liaoning Cheng Da Co Ltd have been -2% over the past three years .

Back to Top